The overall KRAS mutation frequency of 39% is in line with the results from previous studies , though the different mutation rates - 33% in colon cancer and 55% in rectal cancer (p = 0.02) - has not been reported in conjunction with treatment-predictive testing. The gene discussed is KRAS; the disease is rectal cancer.